Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

Axial Spondyloarthritis (axSpA) is a form of arthritis that mainly causes discomfort and inflammation in the spine and ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Novo executives have previously said it is too soon to know the impact of the negotiations on Ozempic. Wojcicki, who has been trying to take the company private since April, proposed to acquire all ...

Overview: Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide with a market cap of approximately $831.58 billion. Operations: Eli Lilly generates revenue primarily ...

According to Benzinga Pro, Eli Lilly's peer group average for short interest as a percentage of float is 4.49%, which means ...

Shares of Eli Lilly & Co. LLY slipped 1.88% to $906.18 Tuesday, on what proved to be an all-around mixed trading session for ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Baron Funds mentioned Eli Lilly and Company (NYSE:LLY) in its Q2 2024 investor letter. Here is what the fund said: ...